Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a for relapse after allogeneic HPCT
ACTRN12612000728831Phase 2Completed
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Jul 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in hematopoietic malignancies, sponsored by Royal Brisbane and Women's Hospital. Primary endpoint: Overall survival. Started Jul 2012; status: completed.
02
Drugs
interferon alfa
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12612000728831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000728831.